Protoplast-Derived Microvesicles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, such as liposomes and minicells, face challenges in targeting specific cells or tissues effectively and can cause side effects due to the presence of toxic materials like endotoxins and peptidoglycans, limiting their therapeutic and diagnostic applications.
Innovation Solution
Microvesicles derived from protoplasts of bacterial, archaeal, or plant cells, which have had their cell walls removed, are used to deliver therapeutic, diagnostic, or vaccine substances to specific cells or tissues, avoiding immune responses and reducing side effects by eliminating toxic components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If minicells derived from Gram-negative bacteria are used for drug delivery, then the delivery system can be formed, but endotoxins in the outer membrane cause systemic inflammation and sepsis
Solution Approach 1:
The patent removes the cell wall from bacterial cells to create protoplasts, thereby extracting and eliminating the harmful endotoxins and peptidoglycans that cause inflammation and sepsis, while retaining the useful cell membrane for drug delivery function
Solution Approach 2:
The patent converts the potentially harmful bacterial cell wall structure into a beneficial protoplast system by removing the wall components that cause toxicity, thereby transforming a harmful feature into a safe and effective delivery vehicle
2Ease of manufacture
If minicells derived from Gram-positive bacteria are used for drug delivery, then the delivery system can be formed, but peptidoglycans in the cell wall cause side effects
Solution Approach 1:
The patent removes the cell wall from bacterial cells to create protoplasts, thereby extracting and eliminating the harmful peptidoglycans that cause side effects, while retaining the useful cell membrane for drug delivery function
3Duration of action of moving object
If liposomes are used for drug delivery, then the drug release profile can be modified, but the liposomes lack the ability to recognize target cells or tissues
Solution Approach 1:
The patent utilizes the natural properties of the bacterial cell membrane to provide both drug delivery control and target recognition capabilities, eliminating the need for artificial modifications by allowing the membrane itself to serve multiple functions
Solution Approach 2:
The patent creates a composite delivery system combining the controlled release properties of liposome-like structures with the target recognition capabilities of biologically derived membranes, achieving both functions through a unified protoplast-based system
4Adaptability or versatility
If targeting ligands are imparted to liposomes, then target binding capability is achieved, but the system has not passed clinical tests and cannot be commercialized
Solution Approach 1:
The patent employs the natural cell membrane components themselves as targeting elements, eliminating the need for separate ligand conjugation steps and reducing the complexity of clinical translation by using inherently biocompatible structures
Data Source
AI summary
The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.